Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Perrin

Showing results (541-550 of 561) with videos related to

Pageof 57
Sort By:
Breast (Edinburgh, Scotland)|November 2, 2019
CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC databaseP Gougis, M Carton, C Tchokothe, et al.
Gynecologic Oncology|May 31, 2021
Corrigendum to "Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial" [Gynecologic Oncology 161 (2021) 143-151]Monika Janda, Kristy P Robledo, Val Gebski, et al.
ESMO Open|February 24, 2022
Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG)C Moreau-Bachelard, L Campion, M Toulmonde, et al.
Molecular Pharmaceutics|August 27, 2021
Preclinical Evaluation of a Fluorescent Probe Targeting Receptor CDCP1 for Identification of Ovarian CancerYaowu He, Tashbib Khan, Thomas Kryza, et al.
Theranostics|February 28, 2020
Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancerBrittney S Harrington, Yaowu He, Tashbib Khan, et al.
British Journal of Cancer|February 17, 2016
Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancerBrittney S Harrington, Yaowu He, Claire M Davies, et al.
Cancers|April 9, 2020
Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian CarcinomaTashbib Khan, Yaowu He, Thomas Kryza, et al.
Oncogene|April 21, 2015
Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistanceY He, A C Wu, B S Harrington, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 31, 2020
Introducing new and repurposed TB drugs: the endTB experienceK J Seung, U Khan, F Varaine, et al.
Cell Reports|June 28, 2018
L1 Retrotransposon Heterogeneity in Ovarian Tumor Cell EvolutionThu H M Nguyen, Patricia E Carreira, Francisco J Sanchez-Luque, et al.
Pageof 57

Showing results (541-550 of 561) with videos related to

Sort By:
Pageof 57
Breast (Edinburgh, Scotland)|November 2, 2019
CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC databaseP Gougis, M Carton, C Tchokothe, et al.
Gynecologic Oncology|May 31, 2021
Corrigendum to "Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial" [Gynecologic Oncology 161 (2021) 143-151]Monika Janda, Kristy P Robledo, Val Gebski, et al.
ESMO Open|February 24, 2022
Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG)C Moreau-Bachelard, L Campion, M Toulmonde, et al.
Molecular Pharmaceutics|August 27, 2021
Preclinical Evaluation of a Fluorescent Probe Targeting Receptor CDCP1 for Identification of Ovarian CancerYaowu He, Tashbib Khan, Thomas Kryza, et al.
Theranostics|February 28, 2020
Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancerBrittney S Harrington, Yaowu He, Tashbib Khan, et al.
British Journal of Cancer|February 17, 2016
Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancerBrittney S Harrington, Yaowu He, Claire M Davies, et al.
Cancers|April 9, 2020
Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian CarcinomaTashbib Khan, Yaowu He, Thomas Kryza, et al.
Oncogene|April 21, 2015
Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistanceY He, A C Wu, B S Harrington, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 31, 2020
Introducing new and repurposed TB drugs: the endTB experienceK J Seung, U Khan, F Varaine, et al.
Cell Reports|June 28, 2018
L1 Retrotransposon Heterogeneity in Ovarian Tumor Cell EvolutionThu H M Nguyen, Patricia E Carreira, Francisco J Sanchez-Luque, et al.
Pageof 57